Development of a T Cell-targeted siRNA Delivery System Against HIV-1 Using Modified Superparamagnetic Iron Oxide Nanoparticles: An In Vitro Study

Kamalzare, Sara; Mobarakeh, Vahid Iranpur; Tekie, Farnaz Sadat Mirzazadeh; Hajiramezanali, Maliheh; Riazi-Rad, Farhad; Yoosefi, Sepideh; Normohammadi, Zahra; Irani, Shiva; Tavakoli, Mohammad Reza; Rahimi, Pooneh; Atyabi, Fatemeh

doi:10.1016/j.xphs.2021.10.018

Cited by 7 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RNA interference is mostly brought on by siRNAs, which mute particular genes at the mRNA level. People have created disease-targeting strategies that connect siRNAs to CD4+ T cells based on this characteristic, with potential applications including HIV therapy [25].…”

Section: Short Interfering Rnas (Sirnas)mentioning

confidence: 99%

The application of epigenetics in CAR-T therapy

Zhang¹

2023

AETR

View full text Add to dashboard Cite

show abstract

Section: Short Interfering Rnas (Sirnas)mentioning

confidence: 99%

The application of epigenetics in CAR-T therapy

Zhang¹

2023

AETR

View full text Add to dashboard Cite

show abstract

“…Gene silencing, however, is reduced compared to unconjugated molecules. This is attributed to the steric hindrance created by the PEG molecule, which hinders docking of the siRNA into RISC [ 116 ]. This hindrance can be overcome by incorporating a linker which holds together the complex during circulation but releases the siRNA inside a cell.…”

Section: Non-viral Delivery Systemsmentioning

confidence: 99%

Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection

et al. 2022

View full text Add to dashboard Cite

Our understanding of HIV infection has greatly advanced since the discovery of the virus in 1983. Treatment options have improved the quality of life of people living with HIV/AIDS, turning it from a fatal disease into a chronic, manageable infection. Despite all this progress, a cure remains elusive. A major barrier to attaining an HIV cure is the presence of the latent viral reservoir, which is established early in infection and persists for the lifetime of the host, even during prolonged anti-viral therapy. Different cure strategies are currently being explored to eliminate or suppress this reservoir. Several studies have shown that a functional cure may be achieved by preventing infection and also inhibiting reactivation of the virus from the latent reservoir. Here, we briefly describe the main HIV cure strategies, focussing on the use of RNA therapeutics, including small interfering RNA (siRNA) to maintain HIV permanently in a state of super latency, and CRISPR gRNA to excise the latent reservoir. A challenge with progressing RNA therapeutics to the clinic is achieving effective delivery into the host cell. This review covers recent nanotechnological strategies for siRNA delivery using liposomes, N-acetylgalactosamine conjugation, inorganic nanoparticles and polymer-based nanocapsules. We further discuss the opportunities and challenges of those strategies for HIV treatment.

show abstract